Most Recent
A class action by frustrated buyers over the $85 million sale of a Sydney development has failed to prevent the sale of lots, with a judge finding the class action's claims lack evidence.
Samsung Bioepis can't get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug.
The ACCC will not oppose Lendlease’s plan to sell a portfolio of residential projects to Stockland for $1.3 billion after accepting Stockland’s plan to divest a project in Illawarra.
Vanguard Investments has been ordered to pay a penalty of almost $13 million for misleading the public about its $1 billion “ethically conscious” hedge fund.
Macquarie Bank has been fined a record $4.995 million for failing to stop the placement of suspicious orders on the electricity futures market.
An insurer has asked the High Court to hear an appeal with implications for competition in the "monopolised" market for lawyers professional indemnity insurance in New South Wales.
If it takes up the Federal Court's ruling in favour of solicitors seeking to earn a cut from a class action, the High Court will be asked to overrule its 2019 decision against common fund orders.
Shareholders in lending platform Marketlend can bring a derivative suit against its directors for allegedly misusing company funds, including spending $1.3 million on barrister chambers fees.
The Fair Work Commission has dismissed a six-year-old unfair dismissal case against Gadens, describing the case as part of an apparent “spiteful campaign” against the firm.
The nephew of Clive Palmer and former director of Queensland Nickel has failed to reverse a decision rejecting his bid to dismiss contempt proceedings related to the company’s collapse.